CCP
MRK icon

Cane Capital Partners’s Merck MRK Stock Holding History

Cane Capital Partners’s Portfolio MRK Stock Details MRK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$411K Buy
3,197
+407
+15% +$47.6K 0.16% 95
2026
Q1 		$336K Sell
2,790
-75
-3% -$8.66K 0.15% 88
2025
Q4 		$302K Buy
+2,865
New +$269K 0.12% 112

Other funds holding MRK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Cane Capital Partners's MRK Position: Q2 2026 in Review

Cane Capital Partners increased its Merck (MRK) stake by 15% in Q2 2026, buying an estimated $47.6K and bringing the position to 3,197 shares worth $411K. The position accounts for 0.16% of the portfolio, ranked #95.

Cane Capital Partners first reported a position in MRK in Q4 2025 and has held it in 3 quarters since. 3,814 funds tracked by Wall St. Rank hold MRK as of Q2 2026.

  • Cane Capital Partners held 3,197 shares of Merck worth $411K as of Q2 2026.
  • Cane Capital Partners bought 407 Merck shares in Q2 2026, an estimated $47.6K.
  • Merck made up 0.16% of Cane Capital Partners's portfolio in Q2 2026, its #95 holding.
  • Cane Capital Partners first reported a position in Merck in Q4 2025 and has held it in 3 quarters since.
  • 3,814 funds tracked by Wall St. Rank held Merck as of Q2 2026.

Based on Cane Capital Partners's 13F filing for Q2 2026, filed 5 Aug 2026.